By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

MediciNova, Inc. 

4350 La Jolla Village Drive, Suite 950

San Diego  California  92122  U.S.A.
Phone: 858-373-1500 Fax: 858-373-7000


SEARCH JOBS


Industry
Biotechnology






Company News
MediciNova, Inc. Release: MN-166 (Ibudilast) ALS Abstract Accepted For Presentation At The 26th International Symposium On ALS/MND In Orlando, FL: Interim Safety And Clinical Outcomes To Be Presented 7/28/2015 7:17:06 AM
MediciNova, Inc. Announces FDA Approval Of The Second Phase II Protocol For MN-001 In NASH Which Targets NASH Patients With Hypertriglyceridemia 7/27/2015 7:11:15 AM
MediciNova, Inc. Announces Update On Development Plans For MN-001 In IPF 7/21/2015 7:22:13 AM
MediciNova, Inc. Announces The Completion Of Enrollment In Clinical Trial Of MN-166 (Ibudilast) In Alcohol Dependence 7/1/2015 6:58:29 AM
MediciNova, Inc. Announces Presentation Of Interim Data From Clinical Trial Of MN-166 (ibudilast) In Alcohol Dependence At The 38th Annual RSA (Research Society On Alcoholism) Scientific Meeting 6/24/2015 7:45:46 AM
MediciNova, Inc. Announces New Article Published On MN-166 (Ibudilast) In Addiction Biology 6/16/2015 7:24:51 AM
MediciNova, Inc. Announces Randomization Of 255 Subjects Completed In Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS 6/12/2015 7:12:08 AM
MediciNova, Inc. Announces FDA Granted Orphan Drug Designation To MN-166 (Ibudilast) For Krabbe Disease 6/3/2015 7:19:03 AM
MediciNova, Inc. Announces Full Enrollment In Phase 2b Trial Of MN-166 (Ibudilast) In Progressive MS 5/7/2015 7:28:58 AM
Baseline Characteristics Of 228 Subjects Enrolled In MediciNova, Inc.'s Phase IIb Trial Of MN-166 (Ibudilast) In Progressive MS Presented At The American Academy of Neurology 67th Annual Meeting 4/23/2015 7:06:45 PM
12345678910...
//-->